Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder...

Area of Science:

• Marine natural products
• Oncology
• Urology

Background:

• Bladder cancer (BC) presents a poor prognosis in advanced stages, with current treatments causing significant adverse events.
• Natural product-based therapies are being explored as alternatives or adjuncts for BC management.
• Fucoidan, derived from marine brown algae, exhibits anti-cancer properties and protective effects against treatment toxicities.

Purpose of the Study:

• To review the anti-cancer effects and molecular mechanisms of fucoidan extracts in bladder cancer.
• To explore the synergistic effects of fucoidan with conventional chemotherapy and novel nanoparticle-based strategies.
• To highlight fucoidan's potential in mitigating cancer-related disorders and chemotherapy-induced adverse events.

Main Methods:

• Literature review of in vivo and in vitro studies on fucoidan's efficacy in various malignancies, including bladder cancer.
• Analysis of molecular mechanisms underlying fucoidan's anti-cancer and protective effects.
• Examination of studies involving fucoidan in combination therapies and nanoparticle formulations.

Main Results:

• Fucoidan demonstrates anti-cancer activity and potential protective effects against cancer-related cachexia and chemotherapy-induced toxicity.
• Studies suggest fucoidan enhances the efficacy of conventional chemotherapeutic agents and shows promise in nanoparticle-based treatments.
• Evidence indicates fucoidan's benefits extend to mitigating cisplatin-induced toxicities.

Conclusions:

• Fucoidan exhibits promising anti-cancer and supportive effects relevant to bladder cancer treatment.
• While promising, current data is insufficient to establish the clinical utility of fucoidan-based therapies for bladder cancer.
• Further research and clinical trials are necessary to determine the optimal application and efficacy of fucoidan in bladder cancer management.